Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06246968 · ClinicalTrials.gov registry record · Phase 1

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

A Phase 1 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
7
Study locations

NCT06246968: Recruiting Phase 1 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06246968 is a Phase 1 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06246968, a Phase 1 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
7
Study locations

Study Summary

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

Primary Outcome

Assess changes in CD4-PD1 in the blood after cryoablation in patients with metastatic or locally advanced triple negative breast cancer (TNBC).

Conditions Studied

Breast Cancer Metastatic Breast Cancer Triple Negative Breast Cancer Metastatic Triple-Negative Breast Carcinoma Triple Negative Breast Neoplasms Breast Cancer Stage IV Locally Advanced Breast Cancer Locally Advanced Triple-Negative Breast Carcinoma

Interventions

  • DRUG Pembrolizumab
  • DEVICE Cryoablation

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-29
Est. Completion 2027-01-29
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT06246968 shows while recruiting

NCT06246968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06246968 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT06246968 about?

NCT06246968 is a clinical study titled "A Study of Pembrolizumab and Cryoablation in People With Breast Cancer". Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

What is the current status of trial NCT06246968?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-01-29. Estimated completion is 2027-01-29.

What conditions does trial NCT06246968 study?

This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Triple Negative Breast Neoplasms.

What interventions are being tested in trial NCT06246968?

The interventions under investigation include: Pembrolizumab (DRUG), Cryoablation (DEVICE).

Who is sponsoring clinical trial NCT06246968?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06246968 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06246968's enrollment target sits among peer trials

30 955th of 1224 higher than 227 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06246968

Source: ClinicalTrials.gov NCT06246968, the US trial registry maintained by the National Library of Medicine. NCT06246968 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.